Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Naples – page 6

1 221 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Naples at a glance
1 221
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 221 trials in Naples

Open in trial search

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Recruiting

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Heart failure with reduced ejection fraction

Recruiting

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Cushing's syndrome

Recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Hepatocellular carcinoma

Recruiting

A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Breast cancer+1

Recruiting

Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Naples

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.

  • Idiopathic Pulmonary Fibrosis
  • COPD Management
  • RSV Prevention

Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.

  • Breast Cancer Prevention
  • Gastrointestinal Cancers
  • Advanced Solid Tumors

Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.

03 Chronic Diseases

Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.

  • Kidney Disease Management
  • Heart Failure Prevention
  • Neurological Disorders

Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.